GlassScriptPhysician profile
Paula Schwartz
NPI 1780769877
$802.79
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2022: $52.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $251.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $134.21 | 2019 | |
| Janssen Biotech, INC. | $129.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.50 | 2019 | |
| Genentech USA, INC. | $56.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.91 | 2019 | |
| Gilead Sciences, INC. | $20.13 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $19.52 | 2019 | |
| Celgene Corporation | $18.10 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.49 | 2019 | |
| Esperion Therapeutics, INC. | $14.78 | 2022 | |
| Pfizer INC. | $12.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.